LY2584702 is primarily investigated for its potential therapeutic applications in cancer treatment. It functions as an inhibitor targeting specific signaling pathways involved in tumor growth and proliferation. Researchers are exploring its efficacy in preclinical and clinical studies to determine its ability to halt cancer progression, particularly in solid tumors. Additionally, its role in combination therapies with other anticancer agents is being evaluated to enhance treatment outcomes. The compound’s ability to modulate key cellular processes makes it a promising candidate for developing targeted cancer therapies. Further research aims to optimize its use and understand its full potential in oncology.